DAVID HOLT: Open Payments
NPI 1912533589 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$966 in 46 payments from 12 companies in 2025. Trend: 2023 $400 · 2024 $441 · 2025 $966
Food & beverage: $966
| Company | Payments | Amount |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 10 | $212 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $125 |
| Teva Pharmaceuticals USA, Inc. | 5 | $105 |
| Collegium Pharmaceutical, Inc. | 5 | $104 |
| PFIZER INC. | 5 | $97 |
| Valinor Pharma, LLC | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: NUZYRA, CAPLYTA, RELISTOR, AUSTEDO XR, Belbuca, MOVANTIK, XHANCE, OCTAGAM IMMUNE GLOBULIN (HUMAN).
Industry payments across AR — which companies pay providers there.
